share_log

Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9

Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9

Stephens & Co.Lifecore Biomedical维持同等权重,目标价上调至9美元
Benzinga ·  2023/09/01 10:51

Stephens & Co. analyst Jacob Johnson maintains Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and raises the price target from $8 to $9.

Stephens&Co.分析师雅各布·约翰逊维持Lifecore Biomedical(纳斯达克:LFCR)的同等权重,并将目标价从8美元上调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发